Current Neuro-Oncology

Volume 28 Number 20
20 July 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 20, 20 July

Shamsan GA, Liu CJ, Braman BC, Li R, Rathe SK, Sarver AL, Ghaderi N, McMahon M, Klank RL, Tschida BR, McFarren SJ, Rosato PC, Masopust D, Sarkaria JN, Clark HB, Rosenfeld S, Largaespada DA, Odde DJ.
Glioblastoma subtypes exhibit distinct migration mechanics and immune responses.
Cancer Res Commun. 2026 Jul 14. doi: 10.1158/2767-9764.CRC-25-0579. PMID: 42447444. ˍ

Yanchu L, Hongbin W, Xiaoli Y, Li Z, Jun W, Meiling R, Xiaoyan Y, Lei L, Feng W.
Pilot report of an anti-PD-1/VEGF bispecific antibody for treating recurrent H3K27M-mutant diffuse midline gliomas.
Cancer Immunol Immunother. 2026 Jul 14. doi: 10.1007/s00262-026-04434-8. PMID: 42446735. ˍ

Carranza O, Pant S, Schuler M, Witt O, Geoerger B, Loriot Y, Farouk Sait S, Arnold D, Dal Molin GZ, Lugowska I, Winter H, Baldini C, Corassa M, Thomas S, Crow L, Xia Y, Triantos S, Sweiti H, Reardon DA.
Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.
JCO Precis Oncol. 2026 Jul 15;10(7):e2501094. doi: 10.1200/PO-25-01094. PMID: 42456086. Trial registration ID: NCT04083976. ˍ

Zhu C, Zeltser N, Oh J, Li CH, Boutros PC.
Sex differences in the cancer proteome.
BMJ Oncol. 2026 Jul 15;5(2):e001130. doi: 10.1136/bmjonc-2026-001130. PMID: 42466117. ˍ

de Jong AM, Kortman ME, Kreek MW, Flies CM, Becker AP, van der Meulen M, de Vos FYFL, Dankbaar JW, Verhoeff JJC, Robe PAJT, Snijders TJ.
Functional outcome after repeat surgery of tumor progression or treatment-associated changes in high-grade glioma: Clinical and radiological predictors.
Neurooncol Pract. 2026 Jan 9;13(4):673-684. doi: 10.1093/nop/npag002. PMID: 42453188. ˍ

Walke V, S S, Agrawal A, Joshi D, Shrivastava A, Sharma T, Tandon A.
Angiogenic Factors in Adult Diffuse Glioma and Their Correlation With Tumor Grade: An Observational Study.
Cureus. 2026 Jun 13;18(6):e110772. doi: 10.7759/cureus.110772. PMID: 42445651. ˍ

Santos JN, Batista FS, Sanches F, Miranda A, Santiago M, Castanheira B, Gonçalves-Nobre JG, Lima P, Nogueira FS, Brito J.
Exceptional Long-Term Disease Stability Under Nivolumab in Recurrent High-Grade Glioma: A Case Report.
Cureus. 2026 Jun 16;18(6):e110942. doi: 10.7759/cureus.110942. PMID: 42465174. ˍ

Ng IB, Jani RH, Goyal A, Pickles A, Prabhu VC, Wainwright DA, Barton K, Thakkar JP.
Single Institution Retrospective Study to Determine Time to First True Progression in MGMT-Methylated Glioblastoma Patients Who Received Standard of Care.
J Clin Med. 2026 Jun 29;15(13):5073. doi: 10.3390/jcm15135073. PMID: 42452534. ˍ

Kurihara H, Narita Y, Ito K, Sato H, Miyakita Y, Takahashi M, Ohno M, Yanagisawa S, Okita NT, Sadachi R, Machida R, Tateishi K, Yoshii Y, Waki A, Hashimoto H, Suzuki H, Zhang MR, Kawamura K, Honda N, Yoshimoto M, Matsumoto H.
First-in-human phase I study of hypoxia-targeting ⁶⁴Cu-ATSM radioligand therapy in patients with malignant brain tumors (STAR-64).
ESMO Open. 2026 Jul 10;11(8):108249. doi: 10.1016/j.esmoop.2026.108249. PMID: 42431136. Trial registration ID: jRCT2091220362. ˍ

Mathen P, Chaudhry H, Mackey M, Cooley-Zgela T, Masciocchi M, Li B, Huang E, Wu J, Smart D, Krauze A, Camphausen K.
Phase I dose escalation of the Exportin 1 inhibitor, Selinexor, in combination with chemoradiation in patients with newly diagnosed glioblastoma.
medRxiv [Preprint]. 2026 Jul 7:2026.06.25.26356263. doi: 10.64898/2026.06.25.26356263. PMID: 42465896. Trial registration ID: NCT04216329. ˍ

Chen Y, Reynolds K, Koch MRA, Petrakian CF, Good Z, Yamada-Hunter S, Sotillo E, Song KW, Mahdi J, Majzner R, Desai MH, Huang YW, Daghagh H, Ehlinger ZJ, Iswari N, Sabatti C, Baggott C, Rietberg SP, Mo KC, Tsui KCY, Hamilton MP, Egeler E, Moon J, Erickson C, Jacobs A, Duh AK, Beebe B, Carr C, Fujimoto M, Kunicki M, Lim AS, Li A, Brown AK, Kuo A, Kaur A, Soundaranayagi SR, Prabhu S, Grant G, Prolo LM, Campen C, Partap S, Davis KL, Feldman SA, Tunuguntla R, Cochran JR, Sahaf B, Heitzeneder S, Monje M, Ramakrishna S, Mackall C.
Anti-CAR Immunity Drives Acquired Therapeutic Resistance to GD2-CAR T Cell Therapy in Diffuse Midline Glioma.
medRxiv [Preprint]. 2026 Jul 9:2026.06.25.26356492. doi: 10.64898/2026.06.25.26356492. PMID: 42465905. Trial registration ID: NCT04196413. ˍ

Lim M, Ye X, Piotrowski AF, Desai A, Ahluwalia MS, Walbert T, Lesser G, Ellingson BM, Peereboom DM, Fisher JD, Desideri S, Jackson C, Pant A, Jain A, Verma R, Oberlton B, Piyadasa H, Bettegowda C, Engle L, Taube J, Bendall SC, Choi J, Drappatz J, Lieberman FS, Kleinberg LR, Pardoll DM, Nabors LB, Wen PY, Grossman SA.
Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.
Nat Med. 2026 Jul 10;32(7):2449-2460. doi: 10.1038/s41591-026-04475-7. PMID: 42432293. Trial registration ID: NCT02658981. ˍ